Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$3.90 USD

3.90
97,084

+0.04 (1.04%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $3.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 250)

Industry: Internet - Commerce

Better trading starts here.

Zacks News

Varian's Halcyon Receives Shonin Approval, Grows in Oncology

Varian Medical (VAR) adopts various strategies to boost the Oncology Segment.

    AmerisourceBergen's PharMEDium Slows Down, Competition Rife

    AmerisourceBergen's (ABC) prospects hurt by tepid performance at PharMEDium. Also, steep competition is a cause for concern.

      Align Technology-Glidewell Dental Deal to Boost iTero Uptake

      Align Technology (ALGN) progresses with deals to boost the Scanners and Services segment.

        Intuitive Surgical Hits a 52-Week High on Solid Prospects

        The market is upbeat about Intuitive Surgical's (ISRG) solid procedure performance in Asia, with growth in China, Japan and Korea.

          Wright Medical (WMGI) Rides on Strong Portfolio & Innovation

          Wright Medical (WMGI) is focused on product innovation through research and development. However, lackluster international performance of the lower extremities segment is a matter of concern.

            Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes

            Revenues at Genomic Health (GHDX) improve year over year in Q3, driven by solid performances in the United States and internationally. However, rising operating losses continue to be a spoiler.

              Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow

              Medtronic's (MDT) latest preliminary sales update for the second quarter of fiscal 2018 holds the market in a bleak light.

                Ecolab (ECL) to Refinance $375M Worth of Notes, Reduce Debt

                Ecolab (ECL) plans to reduce debt by refinancing notes with a lower coupon rate.

                  Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

                  Luminex's (LMNX) collaborative agreements with several companies should help expand the adoption of its products.

                    Intuitive Surgical (ISRG) to Gain From Procedural Business

                    Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.

                      LabCorp Reports New Use of Agilent's Cancer Diagnostic Test

                      The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.

                        Here's Why Investors Should Buy Myriad Genetics Right Now

                        Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.

                          Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

                          Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.

                            Myriad Genetics' Latest Alliance to Boost GeneSight Reach

                            Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base

                              DaVita Issues Downbeat '17 View, Hurricanes Affect Q3 Results

                              Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.

                                Here's Why Investors Should Buy Luminex (LMNX) Right Now

                                Luminex (LMNX) continues to grow strong on innovation and product launches.

                                  Haemonetics (HAE) Grows on Strong Plasma, Competition Rife

                                  Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.

                                    Quest Diagnostics, Clinical Genomics Ally, Oncology Strong

                                    Quest Diagnostics' (DGX) plan to distribute Clinical Genomics' FDA-approved InSure ONE is in line with the company's objective to lead in the high-potential oncology diagnostic market.

                                      Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025

                                      Weight Watchers' (WTW) plan to issue senior notes will aid the company in reducing cost of capital.

                                        Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens

                                        Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.

                                          Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

                                          Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.

                                            BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates

                                            A decline in gross and operating margin was a major drag for BioTelemetry (BEAT) in the third quarter.

                                              Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise

                                              Bruker's (BRKR) recent acquisition of Germany-based MERLIN buoys optimism for its growth within MALDI Biotyper business.

                                                AmerisourceBergen (ABC) Rewards Investors With Dividend Hike

                                                AmerisourceBergen's (ABC) dividend hike adheres to the company's policy of rewarding stakeholders at regular intervals.

                                                  OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3

                                                  OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.